Perakizumab (INN) is a humanized monoclonal antibody designed for the treatment of arthritis.[1] It binds to IL17A and acts as an immunomodulator.[2]

This drug was developed by Genentech/Roche.

References

  1. ^ Statement On A Nonproprietary Name Adopted By The USAN Council - Perakizumab, American Medical Association.
  2. ^ World Health Organization (2012). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 107" (PDF). WHO Drug Information. 26 (2).



Allikas: Https://en.wikipedia.org/wiki/Perakizumab
No tags for this post.